Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldesleukin - Clinigen/Novartis

Drug Profile

Aldesleukin - Clinigen/Novartis

Alternative Names: Chiron IL-2; IL-2; IL-2 - Chiron; interleukin-2 - Chiron; Macrolin™; Proleukin; Recombinant IL-2; Recombinant-human-interleukin-2 - Chiron; T cell growth factor

Latest Information Update: 10 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiron
  • Developer Hyup Jin Corporation; Ligand Pharmaceuticals; Novartis
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Malignant melanoma; Immunodeficiency disorders; Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Discontinued HIV-1 infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Apr 2019 Aldesleukin licensed to Clinigen in worldwide
  • 15 Feb 2019 Clinigen in-licenses Aldesleukin from Novartis in the USA
  • 16 Aug 2017 Prometheus Laboratories terminates a phase II trial due to slow accrual for Malignant melanoma (Metastatic disease, Late-stage disease, Second-line or greater therapy) in USA (IV) (NCT02796352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top